STRATEGIC PLAN

Transcription

1 STRATEGIC PLAN

2 A LONG TERM VISION SERVING THE INNOVATION AND THE ECONOMIC DEVELOPMENT OF THE HEALTH INDUSTRY IN PARIS REGION 1 GOAL By the year 2020, the ambition of Medicen Paris Region is to bring the capital region as one of the three regions of excellence worldwide for personalised and translational medicine. 5 STRATEGIC FIELDS OF ACTION Medicen Paris Region is organizing its operations in the form of 5 strategic fields of action: 4 CHALLENGES > > Structuring the industrial fabric of start-ups, medium and small companies and giving them the capacity to attract multinationals in their open innovation strategies. > > Pulling in world industrial health players. > > Consolidating and strengthening collaborative links and technology transfers from academic and clinical research towards industry. > > Enhancing investor density. The Medicen Paris Region competitiveness cluster stands today as one of the key actors of the Paris region health ecosystem. With more than 220 members, Medicen Paris Region brings together academic, industrial and clinical experts of the pharmaceutical, biotechnologies and medical devices sectors. We recently chose to organize Medicen s operations into five strategic fields of action: In vitro diagnostic, diagnostic and interventional imaging systems, regenerative medicine and biomaterials, ICT for Health and translational medicine. Together, the strategic fields of action commissions include nearly 200 volunteer experts, coming from all backgrounds and working together to build the health ecosystem of tomorrow. Since its founding in 2005, Medicen Paris Region has been contributing to the international attractivity of the health actors of the greater Paris area, a cluster of excellence for personalised medicine and the leading scientific and economic region in Europe in the field of healthcare with almost 71,800 jobs and 4400 public researchers. ARNAUD GOBET Chairman of Medicen Paris Region > > In vitro diagnostic > > Diagnostic and interventional imaging systems > > Regenerative medicine and biomaterials > > ICT for Health > > Translational medicine For each, Medicen Paris Region is mobilizing its members to operate through 4 line action plans: > > Support for innovation by the advent of ambitious public/private collaboration projects. > > International growth and economic development of the companies. > > Training and development in skills. > > Communication. 3 ACTIONS-LEVERS Medicen Paris Region is engaging actions along 3 lines to maintain scientific, technological, economic, industrial and medical competitiveness of the Paris Region health ecosystem: > > Scientific and technological actions designed to encourage the emergence of ambitious solutions. > > A «market» services offer tailored to the needs of the members. > > Well-informed guidance for the public authorities. MEDICEN PARIS REGION IN MEMBERS MAJOR GROUPS MIDDLE SIZE SMALL SIZE FIRMS ACCREDITED AND FUNDED SINCE 2006 PROJECTS BROUGHT TO FRUITION INNOVATING PRODUCTS PUT ON THE MARKET M INVESTMENT OF WHICH M PUBLIC AID 1

3 STRATEGIC FIELDS OF ACTION IN VITRO DIAGNOSTIC 1 Major COS 24 SME 37 MD EUROS Market Major COS 40 SME 5 Major COS 21 SME 250 MD EUROS Market MD EUROS Market 2012 ICT FOR HEALTH TRANSLATIONAL MEDICINE DIAGNOSTIC AND INTERVENTIONAL IMAGING SYSTEMS Legend Companies from Medicen Paris Region involved 3 Major COS 12 SME 6 Major COS 86 SME Major COS SME 110 MD EUROS Market 2020 REGENERATIVE MEDICINE AND BIOMATERIALS 46 SME from Biotech- Products 40 SME CRO / Services Market size 2 3

4 IN VITRO DIAGNOSTIC KEY FIGURES FOR IN VITRO DIAGNOSTIC INVOLVES ALL THE PLAYERS WHO DESIGN, MANUFACTURE AND DISTRIBUTE EQUIPMENT, REAGENTS AND INSTRUMENTS USED FOR OBTAINING MEDICAL INFORMATION FROM BIOLOGICAL SAMPLES TAKEN FROM THE PATIENT. WHAT PERIMETER? Identification, clinical validation and industrialization of biomarkers, trials - predictive companion diagnostics - reagents, innovating laboratory equipment. 4 cutting-edge therapeutic fields: > > Oncology, > > Cardio-metabolism, > > Immuno-infectiology, > > Neuro-degenerative diseases. WHAT ASSETS? The Paris region economic and industrial fabric covers for the 4 major therapeutic fields above: > > All of the application fields of in vitro diagnostic > > haematology cytology, > > biochemistry, > > microbiology, > > immuno-chemistry, > > genetic trials, > > infectious immunology, > > Instruments & services. The Paris region ecosystem of in vitro diagnostic covers more than 40% of the French companies in the field for a total turnover of 990 M. 30 companies in the Paris Region ecosystem are developing R&D activities in the 6 application areas of in vitro diagnostic. WHAT ARE THE TECHNOLOGICAL Making in vitro diagnostic: > > Simple, fast, reliable and low cost for general medicine. > > Usable on latest generation instruments. > > Integrated and totally automated platforms (instruments, consumables, software) for emergency analyses (emergency medical service, resuscitation units, post-resuscitation ICUs). > > Associated with platforms (instruments, consumables, software) for the selective capture of circulating cells and their characterization (circulating cancer cells, immunity/cancer allergy cells, chronic infectious diseases, inflammatory diseases ). > > Accomplished from blood work and samples taken in very small quantities. WHAT ARE THE NON-TECHNOLOGICAL > > Anticipating feasibility in terms of development. > > Demonstrating clinical efficiency and patient benefits from diagnostic innovations. > > Accelerating the validation of innovations by facilitating access of industries to biological samples, simplifying the conditions for IP sharing between the players. > > Defining and directing medical-economic studies so as to be capable of demonstrating the impact on the overall optimizing of health costs and ensuring that they are suitable for use among prescribers. > > Having an influential bearing on technical-regulatory and accreditation issues. MEMBERS: 24 SMALL/MEDIUM COMPANIES, 1 MAJOR GROUP, 15 ACADEMIC BODIES A STRONGLY GROWING MARKET THE ADVENT OF PERSONALISED MEDICINE PERIMETER Market segments Sale to private and hospital analytical laboratories (including offshore diagnostic) Self-test market PROJECTS: ACCREDITED AND FUNDED A REAGENT BIOTECHNOLOGY LINE WITH A STRUCTURED INSTRUMENT MANY ACADEMIC PLATFORMS AND DENSE CLINICAL PRESENCE Market sub-segments Laboratories instruments Biomarkers and laboratory reagents Haematology cytology Biochemistry Microbiology Immuno-chemistry RESEARCH CENTRES: PLATFORMS AND LABORATORIES Major therapeutic fields Cardio-metabolism Oncology Immuno-infectiology Neurosciences Genetic trials Infectious immunology 4 5

5 DIAGNOSTIC AND INTERVENTIONAL IMAGING SYSTEMS KEY FIGURES FOR MEMBERS: 21 SMALL/MEDIUM COMPANIES, 5 MAJOR GROUP, 8 ACADEMIC BODIES PROJECTS: ACCREDITED AND FUNDED RESEARCH CENTRES: HUBS AND PARTNER CLUSTERS MEDICAL IMAGERY EXTENDS TO MEANS OF ACQUISITION, RESTORATION AND ANALYSIS OF BIOLOGICAL IMAGES FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES, USING A VARIETY OF PHYSICAL MEANS: X-RAYS, OPTICS, ULTRASOUND, NUCLEAR MAGNETIC RESONANCE, IMAGERY IS A KEY VECTOR FOR PERSONALISED, GUIDED AND MINIMALLY INVASIVE MEDICINE. WHAT PERIMETER? Identification, validation and industrialization of: > > Imaging markers, in particular imaging biomarkers, > > Decision-support tools, in particular for the guidance of medical acts in vivo, > > Therapeutic targeting and guidance tools. 5 cutting-edge therapeutic fields: > > Neurology, > > Ophthalmology, > > Oncology, > > Cardio-metabolism, > > Osteo-articular. WHAT ASSETS? The French industrial fabric for diagnostic and interventional imagery covers every technological class in the sector and is highly focused in the Paris area: 107 of the 250 listed companies have their R&D and/or production centres in the Paris Region. WHAT ARE THE TECHNOLOGICAL New technologies with a pathology-specific approach: > > The sensitivity and specificity of the imagery tools that go hand in hand with the identification and validation of innovative imagery biomarkers and higher performance sources/detectors. > > The interoperability and a transversal set up for the integration of multimodal data for decision-support tools. > > The development of minimally invasive and personalised treatments based on imagery and theranostics approaches. > > The increased speed of acquisition and/or analysis capacities of the signal and multimodal image processing technologies. WHAT ARE THE NON-TECHNOLOGICAL > > Encouraging access to the innovation market by accelerating the time to patients. > > Making the most of innovation in the field of radiotracer imaging or biomarkers and companion testing in the caregiving process. > > Simplifying image access procedures. > > Enhancing the security of data acquisition and use: management of social, regulatory and associated bioethical dimensions. > > Explaining the regulatory drug delivery approach, devices, therapeutics, > > Integrating imagery biomarkers as the primary endpoint of chemical studies. A GLOBAL MARKET OF $45 BILLION IN 2012 AND $60 BILLION IN 2019 PERIMETER > Diagnostic imaging equipment > Contrast agents and radiotracers 55 stakeholders > Archiving: PACS > Visualisation, postprocedural and merger, CAD 30 stakeholders A VALUE CHAIN THAT IS ESSENTIALLY MADE UP OF INNOVATING SMALL AND MIDDLE SIZE COMPANIES Decision -making tools Imaging devices Targeting and guidance tools A WEALTHY PARIS REGION INDUSTRIAL FABRIC: 107 FIRMS INCLUDING 40 WITH R&D ACTIVITIES > Intra-operative and interventional imaging > Image processing specifically for the procedure: planning, guidance, and CAMI 45 stakeholders Personalised medicine: imaging biomarkers, radiogenomics, minimally invasive procedures. 6 7

6 REGENERATIVE MEDICINE AND BIOMATERIALS KEY FIGURES FOR 2014 REGENERATIVE MEDICINE AND BIOMATERIALS ENCOMPASSES INNOVATING CELLS OR GENE THERAPIES FOR HUMAN USE, PREPARED AT INDUSTRIAL SCALE BY THE INDUSTRY OR MANUFACTURED BY METHODS INVOLVING INDUSTRIAL PROCESSES. THEY PROVIDE NEW WAYS OF REGENERATING, REPAIRING OR REPLACING HUMAN TISSUE. WHAT PERIMETER? Regenerative medicine is an emerging therapeutic strategy aimed at repairing a lesion or a sick organ by replacing injured or sick cells with stem cells or gene therapy. Regeneration can take place in situ by the simulation of damaged organs, or in the laboratory by tissue engineering. 4 cutting-edge fields: > > Gene therapy, > > Somatic cell therapy, > > Products derived from tissue engineering, > > Biomaterials. WHAT ASSETS? In addition to its therapeutic potential, regenerative medicine in the Paris region has the economic potential of creating businesses, growth and jobs. This area has the unique capability of carrying out upstream research activities of excellence, while maximising the industrialization potential of the field. The region concentrates a critical mass of tools unique in Europe and essential for the successful development of regenerative medicine. WHAT ARE THE TECHNOLOGICAL > > Having available validated preclinical cellular and/or animal models. > > Developing bio-production technologies for process industrialization and automation. > > Setting up and having access to clinical grade cellular banks. > > Encouraging and ensuring the security of the industrial sources of biological raw materials. > > Multiplying technologies and devices for tissue engineering and implantation. > > Establishing banks of non-biological materials -matrices and scaffolds under industrial quality requirements. > > Developing and industrializing safe processes to obtain specific cell types: induced pluripotent cells, CSM. > > Extending GMPs in industrialisation and standardisation. WHAT ARE THE NON-TECHNOLOGICAL > > Setting up clinical studies in a faster and more efficient way. > > Simplifying public/private partnerships and improving IP access and management. > > Contributing to validated quality control standards and a European regulation. > > Ensuring the sustainability of the economic model. > > Developing adapted medical-economic evaluation models and a reimbursement policy. > > Qualifying and resolving issues of skill requirements MEMBERS: 12 SMALL/MEDIUM COMPANIES, 3 MAJOR GROUPS, 6 ACADEMIC BODIES PROJECTS: ACCREDITED AND FUNDED RESEARCH CENTRES A GROWING MARKET: $110 BILLION IN 2020 AND $15 BILLION FOR FRANCE IN

7 ICT FOR HEALTH KEY FIGURES FOR 2014 E-HEALTH OFFERS POWERFUL LEVERAGE FOR MODERNIZING AND IMPROVING THE EFFICACY AND EFFICIENCY OF THE HEALTHCARE SYSTEM, WHILE CUTTING EXPENDITURES. IT IS AN OPPORTUNITY TO COPE WITH TODAY S SOCIETAL AND ECONOMIC CHALLENGES: AN AGEING POPULATION, THE DEVELOPMENT OF CHRONIC DISEASES AND AN EQUAL ACCESS TO QUALITY CARE TO BE MAINTAINED. AMONG OTHER THINGS, E-HEALTH TECHNOLOGIES HELP TO IMPROVE THE MONITORING OF CHRONIC DISEASES AND OFFER A BETTER RESPONSE TO INCREASE PATIENTS COMPLIANCE AND ADAPTATION VIA REMOTE ANALYSIS, THUS REDUCING THE EFFECTS OF MEDICAL DESERTS AND SHORTENING HOSPITALIZATION PERIODS. IN THE PARIS REGION, ICT FOR HEALTH STAKEHOLDERS ARE GATHERED TOGETHER UNDER A UNIQUE INCENTIVE OF THREE COMPLEMENTARY TECHNOLOGY CLUSTERS: MEDICEN PARIS REGION, SYSTEMATIC PARIS-REGION AND CAP DIGITAL PARIS-REGION A MEMBERS: 40 SMALL/MEDIUM COMPANIES, 2 MAJOR GROUPS, 18 ACADEMIC BODIES PROJECTS: ACCREDITED AND FUNDED CONSTRUCTIVE AND EFFICIENT PARIS REGION INTER-CLUSTER DYNAMISM A FAST-GROWING FRENCH MARKET: $2.8 BILLION WHAT PERIMETER? E-health contributes to the medical coverage of patients by prevention, screening, diagnostic, monitoring and therapeutic care of pathologies. This corresponds to telemedicine and telehealth solutions at home or in a hospital environment. ICT for Health actions focus on chronic illnesses in the course of the aging process. They are designed to make patients self-sufficient with a medicalised approach. 2 cutting-edge therapeutic fields: > > Cardio-metabolism, > > Neurosciences. WHAT ASSETS? The commission dedicated to ICT for Health in the Paris Region comprises roughly 50 companies (all of which being members of Medicen Paris Region), including four large groups and one small firm. These companies have activities covering every segments of the value chain. WHAT ARE THE TECHNOLOGICAL > > Identifying and validating predictive (bio)markers. > > Miniaturizing and industrializing sensitive and functionalised biosensors. > > Developing algorithms to translate the signal into relevant medical information. > > Setting up strategies for data protection emanating from smart connected devices. WHAT ARE THE NON-TECHNOLOGICAL > > Favouring the development of long-lasting economic models. > > Stimulating the advance of new forms of public buying. > > Measuring the impact of technologies and solutions on the care process. > > Anticipating the social-cultural acceptability and adoption of the developed technologies by users. PERIMETER Pole & Clusters Markets Therapeutic fields Medicen Paris Region Biosensors & other devices With ICT for Health PARTNERS: Systematic Paris-Region / Cap Digital Paris-Region / Finance INNOVATION / Other Poles & clusters Hardware & Software Smart Medical System Chronic diseases in aging, Cardio-metabolism, Oncology. Immuno-infectiology. Neurosciences. Medicen Paris Region e-health solutions Patients Permanent care Payers 10 11

8 TRANSLATIONAL MEDICINE KEY FIGURES FOR TRANSLATIONAL MEDICINE IS A CONCEPT DEFINING A PROCESS OF RESEARCH AND DEVELOPMENT AS WELL AS A SET OF MEANS AND SERVICES TO ACCELERATE THE PATIENTS ACCESS TO THERAPEUTIC AND TECHNOLOGICAL INNOVATIONS. TRANSLATIONAL MEDICINE IS BASED ON 3 MAJOR PRINCIPLES: > > PLACING PATIENTS AND DISEASES AT THE BEGINNING AND END OF THE RESEARCH PROCESS, > > BRINGING ALL THE PLAYERS AND DISCIPLINES INVOLVED IN THE VARIOUS STAGES OF RESEARCH AND DEVELOPMENT CLOSER TO EACH OTHER, > > FACILITATING ACCESS TO THE MOST INNOVATING TECHNOLOGIES AND SERVICES TO UNDERSTAND, MODEL AND FOLLOW UP THE ONSETS AND DEVELOPMENT OF A DISEASE AND THE IMPACT OF THE SOLUTIONS USED. WHAT PERIMETER? WHAT ASSETS? Because of its laboratories, technological platforms, hospital networks and companies, the Paris Region, from the quantitative standpoint, is one of the biggest bio clusters in the world, covering the entire line and the main health industry markets: medicaments, vaccines, bio therapies, diagnostics, imagery, medical devices and telemedicine. Translational medicine concerns directly* 164 companies in the Paris Region, 14 major groups and small companies, 26 preclinical CRO units and 53 clinical CRO units. * Data for 2014 WHAT ARE THE TECHNOLOGICAL > > Developing the tools needed to better unravel the key mechanisms of diseases and the individual characteristics of the patients and their needs. > > Establishing the tools for the development of candidate drugs. MEMBERS PROJECTS: ACCREDITED AND FUNDED RESEARCH CENTRES MARKET: GROWING CLINICAL AND PRECLINICAL CRO UNITS, BIO-COMPUTING AND BIG DATA VENTURES GROWING STRONGLY Preclinical 18 mo Phase 1 N = mo Phases of development of a new drug Phase 2 N = 300 N > mo Phase 3 36 mo Drug Approuval Total time 90 mo (7,5 years) Translational medicine is aimed at accelerating the discovery of new treatment by putting the patient at the centre of a multidisciplinary research process that includes molecular technologies such as sequencing, biomarkers, and metabolomics. Translational medicine strategic field of action is transversal and essential to the four previous. Its activity concentrates on drug discovery, productivity challenges involving the R&D aspects of the pharmaceutical process, and on the services companies (CRO) that are strongly represented in the Paris Region. WHAT ARE THE NON-TECHNOLOGICAL > > Disseminating information about the translational medicine approach to players in different cultures and disciplines. > > Encouraging the emergence of translational medicine excellence centres (CEMT). > > Promoting and having the process of using these innovations adopted. > > Arousing awareness about translational research/ medicine in scientific and medical syllabuses. Biomaker ID Preclinical testing Assay Development Phases of development new biomaker assay linked to new drug Biomaker Selection Signal Correction Assay Performance Hypothesis Testing Stratified or Enriched Assay Validation Clinical Validation Enrichment Co-primary End point Companion Diagnostics Approval 12 13

9 THE DEVELOPMENT OF MEDICEN PARIS REGION COMPANIES MEDICEN PARIS REGION IS DEVOTED TO HELPING ITS MEMBER COMPANIES BY ACCELERATING AND FACILITATING THE MARKET ACCESS OF THEIR VALUE-CREATING TECHNOLOGICAL OFFERS. TECHNOLOGICAL OFFERS: > > For personalised medicine: Tomorrow s medicine is directed towards individualised, preventive medicine, closer to the patient and with a multi-expertise approach. > > For medical and economic benefit The emerging technologies are creating therapeutic innovations and innovations through usage, which will lead to new practices in the hospital & general medicine processes, with medical and economic benefits. > > To address increasingly strict and complex regulation which requires costly investments Putting innovating solutions on the market, and having them covered by health insurance involves long and costly regulatory processes for the manufacturers, involving many stakeholders. The healthcare sector has to find a balancing point between the demands of the regulatory requirements and the care, and the economic size of the markets. > > For patients to become a proactive healthcare player The health system is confronted by structural and economic challenges leading to new opportunities and needs for innovations in therapeutics and medical practices. The merger between medicine, nanotechnologies and ICT is a unique way of getting diagnostic out of the hospital and taking it to the patient. > > For remote medicine The challenges of access to care and of an ageing population bring telemedicine solutions at the heart of new medical services to be established outside the hospital and closer to the patients themselves. The initiative of the three clusters: Medicen Paris Region, Cap Digital Paris-Region and Systematic Paris-Region aims to foster the emergence of collaborative e-health and telemedicine projects. > > Towards personalised medical data management It is essential to be able to anticipate and define the conditions for national independence in the field of massive health data utilisation

10 THE 4 COMMITMENTS OF MEDICEN PARIS REGION TO MAKE THE PARIS REGION THE AREA OF REFERENCE IN THE WORLD OF PERSONALISED MEDICINE AN OFFER OF SERVICES TO THE MEMBERS Medicen Paris Region structures its service portfolio along five pillars: > > Support for innovation, > > Access to financing, > > Company growth, > > International development, > > Training and skills development. This offer of services can be further broken down into 4 disctinct objectives targeting the company needs according to their maturity of development: > > Informing, > > Diagnosing, > > Connecting, > > Accompanying. To find out more: 1/ CONSOLIDATING THE ECONOMIC DEVELOPMENT OF THE COMPANIES BY SUPPORTING: > > Collaborative R&D by the supply of innovating project maturing and collaborative accompanying measures, tailored to the specifications of the various financing inputs. > > Downstream industrialization and processes of putting innovations on national and international markets. > > Providing tool and services for the company development by offering a focused and customised portfolio of services incorporating strategic approach, management, capitalization, market studies, legal and regulatory aspects of the health sector and the management of industrial property. 3/ HIGHLIGHTING THE ADVANTAGES OF THE TERRITORY AND ITS PLAYERS To promote the advantages of its members and the attractiveness of its territory, Medicen Paris Region will strengthen the visibility of local health events, highlighting the results of its actions and those of the other health players in the Paris Region. 4/ COMMITTING TO TRAINING AND SKILLS DEVELOPMENT By acting as a key interface between industrial and academic players, the cluster will strengthen its efforts to answer the training and skills development regional needs. INNOVATION ACCESS TO FUNDING INFORM ACCOMPANY GROWTH 2/ MOBILISING THE SKILLS AND BRINGING THEM TOGETHER DIAGNOSE Developing the health process at the global level involves researching on a national scale with a critical mass of players who are able to exchange, share and act together. Medicen Paris Region will endeavour to coordinate all the players supporting the development of the health sector. ESTABLISH LINKS TRAINING AND SKILLS INTERNATIONAL DEVELOPMENT 16 17

11 STRATEGIC INTERACTIONS BETWEEN MEDICEN PARIS REGION AND ITS ECOSYSTEM LOCATION MEDICEN PARIS REGION DEVELOPS AND COORDINATES THE NECESSARY PARTNERSHIPS FOR THE PARIS REGION TO BECOME THE REFERENCE AREA FOR PERSONALISED MEDICINE. FAVOURING PARTNERSHIPS WITH REGIONAL AND NATIONAL STRUCTURES FOR INNOVATION AND ECONOMIC DEVELOPMENT NUTRITION HEALTH LONGEVITY CLUSTER Lille At the crossroads of nutrition, Biotechnology and Health Innovation for nutrition, Cardiometabolic and neurodegenerative diseases. AS A CLUSTER, MEDICEN PARIS REGION PLAYS A KEY ROLE IN FEDERATING THE DIFFERENT STAKEHOLDERS ALONG STRATEGIC COLLABORATION WITH: > > OTHER TECHNOLOGICAL COMPETITIVENESS CLUSTERS (ROBOTICS, ICT, OPTICS ), > > REGIONAL AND NATIONAL RESEARCH AND ACCOMPANYING STRUCTURES SUPPORTING COMPANIES DEVELOPMENT, > > INTERNATIONAL NETWORKS AND CLUSTERS, > > NATIONAL TRAINING AND SKILLS DEVELOPMENT STRUCTURES (SCHOOLS, UNIVERSITIES). REINFORCING TIES AND INTER-CLUSTER PARTNERSHIPS The seven French health competitiveness clusters work together along their respective specific assets and strategic positioning. The activity of co-labelling innovative projects has been reinforced to ensure the successful emergence of projects at the national scale, and strengthen the global structure of the national health process. Beyond this R&D emergence for personalised medicine, inter-cluster cooperation will address transversal challenges between 2014 and The development of solutions in personalised medicine involves indeed a cross-disciplinary approach and Medicen Paris Region intends to continue building unique cooperation models with complementary technological clusters on the model of the recent initiatives launched in the Paris Region with Cap Digital Paris-Region, Systematic Paris-Region and Finance Innovation. Medicen Paris Region is developing actions to strengthen partnerships with the leading healthcare communities established in the Paris Region. Medicen Paris Region is for instance consolidating existing ties with Leem, Ariis, Aviesan, ARS and AP-HP to bring together the stakeholders of the industry, research, clinics and regional development so that they share an industrial vision based on the current challenges of research and health. Thanks to its deep knowledge of the health process and the strengths of its territory, Medicen Paris Region is particularly skilled in connecting health, innovation, jobs and urban issues together. ENCOURAGING INTERNATIONAL PARTNERSHIPS Over the past few years Medicen Paris Region has developed strategic partnerships with foreign health clusters to increase the visibility of its companies, foster the connection with industrial actors worldwide, promote the emergence of transnational collaborative projects and bring knowledge of foreign markets. In a context of tight international competition, Medicen Paris Region is consolidating its presence in the European networks to strengthen the voice and attractiveness of the Paris Region for the benefit of companies. CONNECTING WITH TRAINING AND SKILLS DEVELOPMENT INSTITUTES Medicen Paris Region is working with its partners to help structure and promote the training models needed for the emerging skills sought by the life sciences actors. Eventually, the training commission of the cluster will be able to issue a label to officially validate the interdisciplinary nature of training programs answering today s education and training challenges. ATLANPOLE BIOTHERAPIES Western France Immunobiotherapies, Radiopharmaceuticals, Regenerative Medicine. CANCER-BIO-SANTE Toulouse & Limoges Cancer: Prevention, Diagnostic, Treatment, Telemedecine, Aging. MEDICEN PARIS REGION Paris In vitro diagnostic, Diagnostic and interventional imaging systems, Regenerative medicine and biomaterials, ICT for Health, Translational medicine. LYONBIOPOLE Lyon & Grenoble in Rhône-Alpes Human medicine, Veterinary medicine, In vitro diagnostic, Medical devices and medical technologies. ALSACE BIOVALLEY Strasbourg Drugs discovery & Medical devices. EUROBIOMED Marseille & Montpellier & Nice in south of France New therapies, Diagnostic, Medical devices, e-health

12 MEDICEN PARIS REGION IN A FEW WORDS CONTACT MEMBERS AT THE HEART OF THE CLUSTER S ACTIONS TO REQUEST ANY INFORMATION, PLEASE CONTACT: > > 5 thematic working groups (strategic fields of action) with the role of supplying consultants to information regarding the governance of Medicen Paris Region thematic areas, and of their development. These commissions are made up of players from the academic, hospital and industrial worlds. > > An R&D project evaluation committee, an independent body that studies R&D projects in order to grant the necessary labelling to them for the subsequent granting of financing by public funding tools. > > A Strategic Orientation Council made up of eight to ten key opinion leaders. > > A Training Commission devoted to assessing and seeking out health and medtech training opportunities offered in the Paris region and to initiating vocational training actions in conjunction with the needs expressed by the strategic fields of action commissions. T: medicen@medicen.org Adress: Medicen Paris Region 3-5 Impasse Reille Paris - FRANCE 20 21

13 MEDICEN PARIS REGION BOOSTS YOUR INNOVATION > > It facilitates the connection of innovation players in the Paris Region. > > It contributes to the emergence and achievement of collaborative innovation projects. > > It accelerates the development of innovating small and middle-sized companies by accompanying them in their economic activity and their international strategy. > > It reinforces the development of an ecosystem on the global scale. MEDICEN PARIS REGION AND ITS PROJECTS ARE SUPPORTED BY